389 related articles for article (PubMed ID: 23962279)
1. Implementation of TPMT testing.
Lennard L
Br J Clin Pharmacol; 2014 Apr; 77(4):704-14. PubMed ID: 23962279
[TBL] [Abstract][Full Text] [Related]
2. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.
Relling MV; Gardner EE; Sandborn WJ; Schmiegelow K; Pui CH; Yee SW; Stein CM; Carrillo M; Evans WE; Klein TE;
Clin Pharmacol Ther; 2011 Mar; 89(3):387-91. PubMed ID: 21270794
[TBL] [Abstract][Full Text] [Related]
3. Thiopurine S-Methyltransferase as a Pharmacogenetic Biomarker: Significance of Testing and Review of Major Methods.
Asadov C; Aliyeva G; Mustafayeva K
Cardiovasc Hematol Agents Med Chem; 2017 Nov; 15(1):23-30. PubMed ID: 28552060
[TBL] [Abstract][Full Text] [Related]
4. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.
Relling MV; Hancock ML; Rivera GK; Sandlund JT; Ribeiro RC; Krynetski EY; Pui CH; Evans WE
J Natl Cancer Inst; 1999 Dec; 91(23):2001-8. PubMed ID: 10580024
[TBL] [Abstract][Full Text] [Related]
5. Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.
Lennard L; Cartwright CS; Wade R; Richards SM; Vora A
Br J Clin Pharmacol; 2013 Jul; 76(1):125-36. PubMed ID: 23252716
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacology and pharmacogenetics of thiopurines.
Sahasranaman S; Howard D; Roy S
Eur J Clin Pharmacol; 2008 Aug; 64(8):753-67. PubMed ID: 18506437
[TBL] [Abstract][Full Text] [Related]
7. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine.
Evans WE; Hon YY; Bomgaars L; Coutre S; Holdsworth M; Janco R; Kalwinsky D; Keller F; Khatib Z; Margolin J; Murray J; Quinn J; Ravindranath Y; Ritchey K; Roberts W; Rogers ZR; Schiff D; Steuber C; Tucci F; Kornegay N; Krynetski EY; Relling MV
J Clin Oncol; 2001 Apr; 19(8):2293-301. PubMed ID: 11304783
[TBL] [Abstract][Full Text] [Related]
8. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update.
Relling MV; Schwab M; Whirl-Carrillo M; Suarez-Kurtz G; Pui CH; Stein CM; Moyer AM; Evans WE; Klein TE; Antillon-Klussmann FG; Caudle KE; Kato M; Yeoh AEJ; Schmiegelow K; Yang JJ
Clin Pharmacol Ther; 2019 May; 105(5):1095-1105. PubMed ID: 30447069
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive study of thiopurine methyltransferase genotype, phenotype, and genotype-phenotype discrepancies in Sweden.
Zimdahl Kahlin A; Helander S; Skoglund K; Söderkvist P; Mårtensson LG; Appell ML
Biochem Pharmacol; 2019 Jun; 164():263-272. PubMed ID: 31005613
[TBL] [Abstract][Full Text] [Related]
10. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells.
Dervieux T; Blanco JG; Krynetski EY; Vanin EF; Roussel MF; Relling MV
Cancer Res; 2001 Aug; 61(15):5810-6. PubMed ID: 11479220
[TBL] [Abstract][Full Text] [Related]
11. Modeling the Outcome of Systematic TPMT Genotyping or Phenotyping Before Azathioprine Prescription: A Cost-Effectiveness Analysis.
Zarca K; Durand-Zaleski I; Loriot MA; Chatellier G; Pallet N
Mol Diagn Ther; 2019 Jun; 23(3):429-438. PubMed ID: 30963516
[TBL] [Abstract][Full Text] [Related]
12. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance.
Yates CR; Krynetski EY; Loennechen T; Fessing MY; Tai HL; Pui CH; Relling MV; Evans WE
Ann Intern Med; 1997 Apr; 126(8):608-14. PubMed ID: 9103127
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia.
McLeod HL; Krynetski EY; Relling MV; Evans WE
Leukemia; 2000 Apr; 14(4):567-72. PubMed ID: 10764140
[TBL] [Abstract][Full Text] [Related]
14. Reducing risk in thiopurine therapy.
Marinaki AM; Arenas-Hernandez M
Xenobiotica; 2020 Jan; 50(1):101-109. PubMed ID: 31682552
[TBL] [Abstract][Full Text] [Related]
15. Understanding thiopurine methyltransferase polymorphisms for the targeted treatment of hematologic malignancies.
Franca R; Braidotti S; Stocco G; Decorti G
Expert Opin Drug Metab Toxicol; 2021 Oct; 17(10):1187-1198. PubMed ID: 34452592
[TBL] [Abstract][Full Text] [Related]
16. Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine.
Dervieux T; Médard Y; Verpillat P; Guigonis V; Duval M; Lescoeur B; Suciu S; Vilmer E; Jacqz-Aigrain E
Leukemia; 2001 Nov; 15(11):1706-12. PubMed ID: 11681411
[TBL] [Abstract][Full Text] [Related]
17. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?
Sanderson J; Ansari A; Marinaki T; Duley J
Ann Clin Biochem; 2004 Jul; 41(Pt 4):294-302. PubMed ID: 15298741
[TBL] [Abstract][Full Text] [Related]
18. Analytic aspects of monitoring therapy with thiopurine medications.
Armstrong VW; Shipkova M; von Ahsen N; Oellerich M
Ther Drug Monit; 2004 Apr; 26(2):220-6. PubMed ID: 15228169
[TBL] [Abstract][Full Text] [Related]
19. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
Levinsen M; Rosthøj S; Nygaard U; Heldrup J; Harila-Saari A; Jonsson OG; Bechensteen AG; Abrahamsson J; Lausen B; Frandsen TL; Weinshilboum RM; Schmiegelow K
Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948
[TBL] [Abstract][Full Text] [Related]
20. Severe pancytopenia and aspergillosis caused by thioguanine in a thiopurine S-methyltransferase deficient patient: a case report.
de Hoogd S; Wong DR; de Vries DR; Harmsze AM
Eur J Gastroenterol Hepatol; 2019 Dec; 31(12):1592-1596. PubMed ID: 31464791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]